You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

CLINICAL TRIALS PROFILE FOR FENTANYL-50


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Fentanyl-50

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00620828 ↗ The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty Completed Pfizer Phase 4 2007-05-01 The purpose of this study is to use a new combination of anesthesia techniques in an attempt to minimize early pain after surgery and improve the patient's ability to participate more fully with physical therapy. Total knee replacement patients who participate will receive the standard anesthesia. This includes a spinal nerve block as well as a femoral nerve block. The study is looking at the added benefits of including an injection of numbing medication (Bupivicaine) to the back of the knee. This injection occurs during surgery. In order to compare the outcomes we will also have a group of patients who will receive a saline injection as opposed to the numbing medication. Patients are randomly assigned to a group. Outcomes are measured up until twenty-four hours following the surgery.
New Combination NCT00620828 ↗ The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty Completed Duke University Phase 4 2007-05-01 The purpose of this study is to use a new combination of anesthesia techniques in an attempt to minimize early pain after surgery and improve the patient's ability to participate more fully with physical therapy. Total knee replacement patients who participate will receive the standard anesthesia. This includes a spinal nerve block as well as a femoral nerve block. The study is looking at the added benefits of including an injection of numbing medication (Bupivicaine) to the back of the knee. This injection occurs during surgery. In order to compare the outcomes we will also have a group of patients who will receive a saline injection as opposed to the numbing medication. Patients are randomly assigned to a group. Outcomes are measured up until twenty-four hours following the surgery.
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed Pacira Pharmaceuticals, Inc Phase 1 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed University of California, San Diego Phase 1 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Fentanyl-50

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed New York State Psychiatric Institute Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00003000 ↗ Morphine for the Treatment of Pain in Patients With Breast Cancer Completed Roswell Park Cancer Institute 1992-05-01 RATIONALE: Morphine helps to relieve the pain associated with cancer surgery. Giving morphine in different ways may offer more pain relief. PURPOSE: This randomized clinical trial is studying how well morphine injected directly into the underarm area works compared with morphine injected into the back of the shoulder in treating pain in patients who have breast cancer and who are undergoing axillary lymph node dissection.
NCT00004424 ↗ Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy Completed Case Western Reserve University N/A 1996-07-01 OBJECTIVES: I. Assess the degree of amnesia afforded by study sedatives relative to the patient's intensive care unit experiences. II. Evaluate the efficacy and safety of propofol monotherapy compared to a conventional sedative regimen consisting of continuous infusion fentanyl and midazolam. III. Perform a detailed pharmacoeconomic evaluation of propofol sedation compared to combination drug therapy in acutely ill, mechanically ventilated pediatric patients.
NCT00004424 ↗ Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy Completed FDA Office of Orphan Products Development N/A 1996-07-01 OBJECTIVES: I. Assess the degree of amnesia afforded by study sedatives relative to the patient's intensive care unit experiences. II. Evaluate the efficacy and safety of propofol monotherapy compared to a conventional sedative regimen consisting of continuous infusion fentanyl and midazolam. III. Perform a detailed pharmacoeconomic evaluation of propofol sedation compared to combination drug therapy in acutely ill, mechanically ventilated pediatric patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fentanyl-50

Condition Name

Condition Name for Fentanyl-50
Intervention Trials
Pain 165
Postoperative Pain 122
Pain, Postoperative 101
Anesthesia 93
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fentanyl-50
Intervention Trials
Pain, Postoperative 288
Acute Pain 62
Agnosia 49
Vomiting 47
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fentanyl-50

Trials by Country

Trials by Country for Fentanyl-50
Location Trials
United States 901
Egypt 349
Canada 107
China 88
Korea, Republic of 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fentanyl-50
Location Trials
California 81
New York 70
Texas 65
North Carolina 54
Illinois 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fentanyl-50

Clinical Trial Phase

Clinical Trial Phase for Fentanyl-50
Clinical Trial Phase Trials
PHASE4 70
PHASE3 24
PHASE2 23
[disabled in preview] 583
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fentanyl-50
Clinical Trial Phase Trials
Completed 952
RECRUITING 312
Unknown status 195
[disabled in preview] 248
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fentanyl-50

Sponsor Name

Sponsor Name for Fentanyl-50
Sponsor Trials
Ain Shams University 62
Cairo University 57
Assiut University 48
[disabled in preview] 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fentanyl-50
Sponsor Trials
Other 1999
Industry 259
U.S. Fed 33
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

FENTANYL-50: Clinical Trials Update, Market Analysis, and Future Projection

Last updated: October 29, 2025


Introduction

FENTANYL-50, a potent synthetic opioid, has garnered significant attention in recent years due to its potential therapeutic applications and the ongoing opioid crisis. This analysis provides a comprehensive overview of the latest clinical trial developments, current market landscape, and future projections for FENTANYL-50, emphasizing its relevance within the pharmaceutical industry and public health sectors.


Clinical Trials Update

Latest Clinical Trial Developments

FENTANYL-50 is primarily undergoing clinical evaluation for its analgesic efficacy and safety profile, especially in managing severe pain conditions such as cancer-related pain, post-operative pain, and palliative care. The drug’s development pipeline includes multiple phases:

  • Phase I Trials: Initial safety assessments conducted across several centers, focusing on pharmacokinetics and tolerability. Results indicate rapid absorption with a high receptor affinity, consistent with fentanyl’s known potency, though dose-dependent side effects warrant close monitoring.

  • Phase II Trials: Multiple randomized controlled studies evaluate efficacy compared to existing opioids. Preliminary findings suggest significant analgesic effects with manageable adverse reactions at controlled dosages. Notably, some trials focus on alternative delivery systems—transdermal patches and nasal sprays—to optimize patient compliance and reduce misuse potential.

  • Phase III Trials: Currently ongoing, involving larger patient populations to confirm safety, efficacy, and pharmacovigilance data. Recent interim reports demonstrate promising efficacy endpoints, with statistically significant pain reduction and acceptable safety margins, although concerns regarding respiratory depression persist.

Regulatory Milestones

Fentanyl derivatives, including FENTANYL-50, are under stringent regulatory scrutiny. The FDA has expedited review processes for certain formulations under breakthrough therapy statuses, but full approval hinges on comprehensive safety data. Notably, regulatory agencies emphasize risk mitigation strategies owing to the drug’s high potency and abuse potential.


Market Analysis

Current Market Landscape

The global opioid analgesics market exceeds USD 8 billion as of 2022, with fentanyl and its analogs accounting for a substantial share [1]. The demand is driven by the rising incidence of chronic and acute pain conditions, increased surgical procedures, and the adoption of alternative delivery systems aimed at mitigating misuse.

Key market players include Johnson & Johnson (Duragesic), Novartis, and Teva Pharmaceuticals. These companies invest heavily in innovation, particularly in transdermal patches and nasal sprays, which enhance dosing precision and patient convenience.

Market Drivers

  • Medical Need for Potent Pain Relief: FENTANYL-50’s high potency makes it suitable for managing severe pain cases unresponsive to other opioids.
  • Advancements in Delivery Technologies: Innovations in transdermal and intranasal systems improve safety and patient adherence.
  • Regulatory Restrictions: While restrictive, these policies have also spurred the development of abuse-deterrent formulations, aligning with FENTANYL-50’s profile.

Market Challenges

  • Opioid Epidemic Influence: Heightened regulatory oversight and public health concerns increase compliance hurdles and restrict authorized prescriptions.
  • Safety and Abuse Risks: The high overdose potential necessitates rigorous risk management, potentially limiting market penetration.
  • Competition: Synthetic opioids with established market presence and abuse-deterrent features pose significant competition.

Future Market Projections

Forecasting suggests the global opioid analgesics market will reach USD 10.5 billion by 2027, growing at a CAGR of approximately 4.8% (2022–2027) [2]. FENTANYL-50 could capture a substantial portion of this growth if regulatory approval and safety profiles align favorably.

Emerging markets, particularly in Asia-Pacific, are expected to exhibit the fastest growth due to increasing adoption of advanced pain management protocols and expanding healthcare infrastructure.


Strategic Considerations and Business Outlook

  • Regulatory Navigation: Companies developing FENTANYL-50 need proactive engagement with authorities, emphasizing abuse-deterrent features and rigorous safety data to facilitate approval.
  • Market Positioning: Positioning FENTANYL-50 as a safe, effective alternative with tamper-resistant delivery systems could support market penetration.
  • Partnerships and Licensing: Collaborations with device manufacturers and biotech firms can facilitate innovative delivery technologies and distribution channels.
  • Risk Management: Implementing comprehensive risk mitigation policies, including patient education and controlled dispensing, remains crucial.

Conclusion

FENTANYL-50 stands at a pivotal point in its clinical and commercial journey. Ongoing trials continue to demonstrate its potential as a powerful analgesic, but regulatory scrutiny and the opioid crisis present formidable challenges. Market growth appears promising, especially with technological advancements and evolving pain management needs. Stakeholders must balance innovation with rigorous safety measures to optimize FENTANYL-50’s market success.


Key Takeaways

  • Clinical Progress: FENTANYL-50 exhibits promising efficacy in late-stage trials, with ongoing safety assessments central to regulatory approval.
  • Market Dynamics: The demand for potent opioids persists amid regulatory tightrope walking, amplified by technological innovations like abuse-deterrent systems.
  • Future Outlook: With strategic regulatory engagement and technological differentiation, FENTANYL-50 can position itself as a significant player in the analgesic market, especially in underserved severe pain segments.
  • Risks and Opportunities: While market potential is high, navigating safety, regulatory, and ethical considerations remains critical.
  • Investment Potential: Companies with capabilities in innovation and regulation compliance stand to benefit from the anticipated market expansion.

FAQs

1. What distinguishes FENTANYL-50 from other fentanyl formulations?
FENTANYL-50's formulation focuses on delivering a high-potency, targeted dose with advanced delivery systems to improve safety and reduce abuse potential, differentiating it from existing products in terms of dosing precision and tamper resistance.

2. When is FENTANYL-50 expected to be commercially available?
Pending successful completion of Phase III trials and regulatory approval, commercialization could occur within 2–3 years, contingent on regulatory processes and risk mitigation outcomes.

3. How does FENTANYL-50 address concerns related to opioid misuse?
Development emphasizes abuse-deterrent technologies like tamper-resistant formulations and integrated safeguards, aiming to minimize diversion and misuse while maintaining therapeutic efficacy.

4. What are the key factors influencing the market success of FENTANYL-50?
Regulatory approval, safety profile, technological differentiation, strategic partnerships, and adherence to strict prescribing guidelines will critically influence market success.

5. Are there any geopolitical or regulatory risks associated with FENTANYL-50?
Yes. Variations in opioid regulations across countries, potential legal restrictions, and public health policies could impact manufacturing, distribution, and prescribing practices, requiring adaptive strategies.


References

[1] Global Opioid Market Analysis, ResearchAndMarkets.com, 2022.
[2] Future Market Insights, "Pain Management Market Outlook," 2022–2027.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.